Literature DB >> 21809177

Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.

Yasunori Fujimoto1, Naoya Hashimoto, Manabu Kinoshita, Yuko Miyazaki, Satoshi Tanaka, Takayuki Yakushijin, Tetsuo Takehara, Naoki Kagawa, Toshiki Yoshimine.   

Abstract

Hepatitis B virus (HBV) reactivation during anticancer chemotherapy or immunosuppressive therapy in chronic carriers can lead to fatal liver failure. We report a rare case of severe HBV reactivation during postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) for malignant glioma. A 49-year-old Japanese woman with a history of HBV carrier status with positive results for hepatitis B surface antigen presented with persistent headache due to a tumor in the left frontal lobe. The tumor was partially resected and anaplastic astrocytoma was diagnosed. Postoperative liver function was normal and radiotherapy plus concomitant and adjuvant TMZ was started. Impaired liver function became apparent just before administration of adjuvant TMZ, and acute liver failure developed. Antiviral therapy including entecavir, a nucleoside analog, led to a successful outcome and the patient survived. This case underlines the possibility of HBV reactivation due to TMZ and suggests the utility of HBV screening and antiviral prophylaxis before administration of TMZ to patients with malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809177     DOI: 10.1007/s10147-011-0294-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  21 in total

1.  Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.

Authors:  R Idilman
Journal:  Gut       Date:  2006-08       Impact factor: 23.059

2.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

3.  Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.

Authors:  M G Chheda; J Drappatz; N J Greenberger; S Kesari; S E Weiss; D C Gigas; L M Doherty; P Y Wen
Journal:  Neurology       Date:  2007-03-20       Impact factor: 9.910

4.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

5.  Hepatitis B virus DNA contains a glucocorticoid-responsive element.

Authors:  R Tur-Kaspa; R D Burk; Y Shaul; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

6.  Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale.

Authors:  Junko Tanaka; Tomiko Koyama; Masaaki Mizui; Shigeru Uchida; Keiko Katayama; Junko Matsuo; Tomoyuki Akita; Ayumu Nakashima; Yuzo Miyakawa; Hiroshi Yoshizawa
Journal:  Intervirology       Date:  2011-03-30       Impact factor: 1.763

7.  Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan.

Authors:  Seiichiro Fujisaki; Yoshiyuki Yokomaku; Teiichiro Shiino; Tomohiko Koibuchi; Junko Hattori; Shiro Ibe; Yasumasa Iwatani; Aikichi Iwamoto; Takuma Shirasaka; Motohiro Hamaguchi; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2011-01-19       Impact factor: 5.948

8.  Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Authors:  R M Galbraith; A L Eddleston; R Williams; A J Zuckerman
Journal:  Lancet       Date:  1975-09-20       Impact factor: 79.321

9.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

View more
  4 in total

Review 1.  Medical management of brain tumors and the sequelae of treatment.

Authors:  David Schiff; Eudocia Q Lee; Lakshmi Nayak; Andrew D Norden; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2014-10-30       Impact factor: 12.300

2.  Hepatitis B virus reactivation during temozolomide administration for malignant glioma.

Authors:  Takuhiro Shoji; Masayuki Kanamori; Jun Inoue; Ryuta Saito; Yoshinari Osada; Yoshiteru Shimoda; Masashi Chonan; Hiroshi Uenohara; Atsushi Masamune; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2020-10-28       Impact factor: 3.402

3.  Hepatitis B Reactivation After Ifosfamide Therapy for Retroperitoneal Sarcoma.

Authors:  Purva Chhibar; Ziqiang Zhu; Naga K S Cheedella; Rashid Chaudhry; Jen Chin Wang
Journal:  Am J Case Rep       Date:  2016-06-01

4.  Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.

Authors:  Ryutaro Furukawa; Hirokuni Homma; Tomohiro Inoue; Hajime Horiuchi; Kazuhiro Usui
Journal:  Intern Med       Date:  2018-05-18       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.